CD4þT cells and their related cytokines play an important role in the pathogenesis of psoriasis, a chronic, recurrent, inflammatory skin disease. The role of IL-35, an immunosuppressive cytokine involved in many autoimmune diseases, in the pathogenesis of psoriasis is unclear. In this study IL-35 expression and its clinical significance in patients with psoriasis were evaluated. Protein and mRNA levels of specified markers were measured by ELISA and qRT-PCR, respectively. It was found that plasma IL-35 concentrations were lower in patients with psoriasis than in healthy individuals (Z ¼ À6.525, P < 0.0001). mRNA titers of Ebi3 and p35 were lower in peripheral blood mononuclear cells from patients with psoriasis than in those from healthy individuals (Z ¼ À5.078, P < 0.0001; Z ¼ À2.609, P ¼ 0.009, respectively). The areas under the receiver-operating characteristic (ROC) curves for IL-35, Ebi3 and p35 in patients with psoriasis versus controls were 0.86, 0.78 and 0.64, respectively. Pearson correlation analysis showed that, in patients with psoriasis, plasma IL-35 expression correlated negatively with concentrations of INF-g, tumor necrosis factor-alpha, IL-23, À17, and À22, and the Psoriasis Activity and Severity Index and positively with concentrations of transforming growth factor beta and IL-10 . In summary, IL-35 may mediate pathogenesis of psoriasis by influencing expression of Th1/Th17/T reg -related cytokines and may therefore be a putative target for monitoring or treating psoriasis.
expressed in the peripheral circulation and skin tissues of patients with psoriasis, are both positively correlated with the PASI (1, 5) . T reg are regulatory T cells that play a dominant role in maintaining immune tolerance, they mainly produces cytokines such as TGF-b and IL-10 and can inhibit the functions of other pathogenic Th1 cells (mainly release of IFN-g) and Th17 cells (mainly release of IL-17 and IL-23), thus limiting development of chronic inflammatory disease and autoimmune disease, as previously reported (6) . However, the relationship between the functions of Th17 and its related cytokines, such as IL-17 and IL-23, and T reg cells remains unknown.
Interleukin 35, an immunosuppressive cytokine, is composed of two subunits (p35 and Ebi3) (7) . A member of the IL-12 family, IL-35 mediates activation of T reg cells and inhibition of effector T cells (8) . In a previous study, it was found that Foxp3þ T cells coexpress p35 and Ebi3 (8) . Deficient expression of either subunit interferes with the inhibitory function of T reg cells in vitro and \results in poor control of inflammatory bowel disease in vivo (8) . Exposure to IL-35 activates CD4þCD25þFoxp3þ T cells, leading to strong expression of IL-10 and inhibition of effector T cells (9) . As Zhang et al. have reported, in a typical psoriasis model, namely the keratin 14 K14-vascular endothelial growth factor A-transgenic mouse model, expression of IL-10 and counts of CD4þCD10þ or CD4þCD25þFoxp3þ T cells in the peripheral blood increase markedly after treatment with IL-35, indicating that IL-35 plays a critical role in dysregulation of the immune system in pathogenesis of psoriasis (10) .
Despite extensive research on psoriasis, the role of IL-35 in its pathogenesis remains incompletely understood. We therefore examined expression of the IL-35 protein in plasma from patients with psoriasis as well as relative strength of mRNA expression of p35 and Ebi3 in PBMCs. We then analyzed the clinical significance of IL-35 expression to determine its potential usefulness for monitoring the disease process as well as its possible use as a novel therapeutic target in psoriasis.
MATERIALS AND METHODS

Subjects
This retrospective study used peripheral blood samples that had been obtained from patients with psoriasis and healthy individuals in Changhai Hospital and Changzhen Hospital, Shanghai, China, between April 2012 and December 2016. The samples were obtained from 55 patients with psoriasis (10 women, 45 men; mean age 44.87 years, range 22-55 years) who were designated as the psoriasis group. Detailed patient characteristics are shown in Table 1 . Patients whose blood was used in this study had clinical and histopathological evidence of psoriasis, had received no systemic therapy for at least 8 weeks, and had no infectious or immune diseases. The activity or severity of this disease was evaluated by PASI scores. Patients were excluded if they had other autoimmune or inflammatory diseases, other infectious diseases, hepatic disease or other diseases that could affect the variables examined in this study.
Blood from 55 healthy individuals (11 women, 44 men; mean age 42.82 years, range 30-55 years) who were designated as the healthy control group, was also examined. Age and sex distributions were similar in the control and psoriasis groups (P > .05; Table 1 ). This study was approved by the Medical Research Ethics Committee of the Second Military Medical University and was conducted in accordance with the provisions of the Declaration of Helsinki (as revised in Fortaleza, Brazil, October 2013). Written informed consent was obtained from all participants prior to enrollment.
Collection of PBMCs and plasma
Peripheral blood samples were split into two portions. One portion was centrifuged at 1800 g for 10 minutes and the resultant plasma stored at À80°C and the other 
Isolation of total RNA and qRT-PCR
Samples PBMCs were thawed, mixed with chloroform, and centrifuged at 12,000 g for 5 min at 4°C. The water phase was mixed with isopropyl alcohol, placed at room temperature for 30 min, and then centrifuged at 12,000 Â g for 15 minutes at 4°C. Nucleic acid in the resulting supernatant was re-precipitated by adding precooled 75% alcohol to the tube. After drying for 2 to 5 min, RNA was resuspended with RNase-free water and tested in a Nanodrop 2000 (Thermofisher). RNA was considered to be purified when the OD of absorption at 260 nm/280 nm exceeded 1. 
ELISA for IL-35 and other cytokines in plasma
Strength of protein expression of IL-35 and other cytokines in plasma samples from patients with psoriasis and healthy individuals were measured by ELISA (human IL-35 Elisa kit ARG81146, human IFN-g Elisa kit ARG80117, human TNF-a Elisa kit ab181421; Abcam, Shanghai, China); the other Elisa kits were all from Arigo (Shanghai, China). All of the steps and calculations were performed in accordance with the protocols provided by the manufacturer. The results were repeated three times and mean values calculated.
Statistical analysis
Normally distributed data are presented as mean AE SD and non-normally distributed data as mean median (range). Continuous variables were compared between the in two groups by two independent samples t-tests or Mann-Whitney tests. Their correlations were determined by Pearson coefficient. All statistical results were obtained using IBM SPSS Statistics 21.0. The tested level (a) was 0.05. ROC curves were constructed using GraphPad Prism 6.0.
RESULTS
Concentrations of IL-35 protein in plasma and relative amounts of mRNA of IL-35 subunits in PBMCs
The mean concentration of IL-35 protein in plasma samples from patients with psoriasis was 2.67 (1.38-21.81) ng/mL and from healthy individuals 7.92 (2.88-41.07) ng/mL (Fig. 1a) (Z ¼ À6.525, P < 0.0001). According to qRT-PCR, the relative amount of Ebi3 mRNA in PBMCs from the psoriasis group was 0.56 (0.01-1.39) compared with 1.01 (0.28-2.82) for the healthy control group (Z ¼ À5.078, P < 0.0001) (Fig. 1b) . Relative p35 mRNA expression in PBMCs from patients with psoriasis was 0.87 (0.03-2.28) compared with 1.21 (0.04-2.95) in healthy controls (Z ¼ À2.609, P ¼ 0.009; Fig. 1c ). Plasma IL-35 concentrations and relative amounts of mRNA of Ebi3 and p35 were negatively correlated with PASI score (r ¼ À0.544, À0.379, À0.415, all P < 0.01, details shown in Fig. 1d-f) .
ROC curves for IL-35, Ebi3, p35 are shown in Figure 1g . The areas under the ROC curves were 0.86, 0.78 and 0.64, respectively, implying that they can accurately distinguish patients with psoriasis from healthy individuals. The largest area under the curve (0.86) was for plasma IL-35 concentrations and the second for Ebi3.
Correlation of plasma IL-35 with cytokine concentrations
Using ELISA kits, plasma concentrations of Th1-related (IFN-g), Th17-related (IL-23, IL-17, IL-22), T reg -related (IL-10, TGF-b) molecules and other related cytokines were determined (Fig. 2a) Fig. 2a ).
In patients with psoriasis, IL-35 concentrations were negatively correlated with IFN-g concentrations (r ¼ À0.471, P < 0.0001; Fig. 2b ), TNF-a (r ¼ À0.595, P < 0.0001; Fig. 2c ), IL-17 (r ¼ À0.436, P ¼ 0.001; Fig. 2d ), IL-22 (r ¼ À0.358, P ¼ 0.007; Fig. 2e) , and IL-23 (r ¼ À0.364, P ¼ 0.006; Fig. 2f ). Plasma IL-35 concentrations were positively correlated with TGF-b and IL-10 concentrations (r ¼ 0.523, 0.487, respectively; both P < 0.0001) (Fig. 2g-h ).
DISCUSSION
Psoriasis is a recurrent inflammatory skin disease mediated by immunoregulatory dysfunction. Its pathogenesis is complex, being characterized by excessive hyperproliferation of keratinocytes and marked infiltration of leukocytes, such as T lymphocytes, monocytes and DCs, into the damaged dermis and epidermis. In addition, some studies have shown intralesional neovascularization (2). Recent studies have increasingly focused on immune cells and their related cytokines in the pathogenesis of psoriasis. Immune factors participating in the development of psoriasis are mainly Th1/Th2 and Th17/T reg as well as related cytokines, such as IFN-g, TNF-a, IL-23, IL-17, IL-22 and TGF-b (1, 2) . In the present study, we examined expression of IL-35 in patients with psoriasis and analyzed its relationship with the abovementioned cytokines to assess its clinical significance in diagnosing or monitoring this disease. A member of the IL-12 family, IL-35 not only has an immunosuppressive function in autoimmune and/or autoinflammatory diseases, but also reportedly has proand/or anti-inflammatory effects in diseases such as rheumatoid arthritis (7, 8, 11, 12) . In one study of patients with ulcerative colitis and Crohn disease, serum IL-35 concentrations were found to be dramatically lower than in healthy individuals and to have a moderate negative correlation with Mayo scores in ulcerative colitis (11) . In CIA, a mouse model of rheumatoid arthritis, IL-35 gene transfer can result in a considerable increase in clinical scores for CIA, associated with a high Th17/T reg ratio in the spleen (13); these findings are in accordance with the upregulation of IL-35 at inflammatory sites as a pro-inflammatory molecule in rheumatoid arthritis reported by Filkov a et al. (12) . However, in Borrelia-vaccinated and Àinfected mice, IL-35 reportedly does not exert an anti-inflammatory effect or reduce the severity of arthritis by inhibiting production of IL-17 (14) , which is in contrast with Li et al.'s findings that IL-35 treatment inhibits development of arthritis, accompanied by lower concentrations of IL-17, in mice with CIA (15) . Some research has shown that IL-35, produced mainly by T reg , promotes the inhibitory function of T reg and inhibits T cells such as Th1/Th2, that are implicated in many autoimmune or inflammatory diseases (16) . T reg lacking p35 and Ebi3 reportedly have reduced regulatory function with regard to limiting T-cell proliferation in a mouse model (8) . Many research groups have studied IL-35 in immune or inflammatory diseases; for example, in a CIA animal model, IL-35-Fc decreases disease activity (9) . Furthermore, IL-35 released from inducible costimulatory-positive regulatory T cells reduces airway hypersensitivity, probably through expression of IL-17 in a mouse model (17) . In idiopathic thrombocytopenic purpura, IL-35 concentrations are positively correlated with numbers of circulating platelets and T reg cells, but negatively correlated with the number of Th1 cells (18) . Additionally, there are reports that exposure to IL-35 induces proliferation of CD4þCD25þFoxp3þ T cells, expression of IL-10 and functional inhibition of effector T cells (9, 19) . In some skin diseases such as pemphigus, an autoimmune disease that causes blistering, treatment with IL-35 is reportedly an efficient therapeutic strategy that can limit progression of this disease (20) . In systemic sclerosis, IL-35 is increased in the fibroblasts of the skin and dermis in a TGF-b-dependent manner, even at early stages of this disease (21) . In contrast, in the keratin 14-VEGF-A-transgenic mouse model, IL-35 has different functions in regulating innate or adaptive immune reactions. For example, the IL-10 concentrations or the number of CD4þCD10þ or CD4þCD25þFoxp3þ T cells can be dramatically induced by IL-35; however, this cytokine can decrease the total number of macrophages and lower the ratio of M1/M2 macrophages, which are dominant in the innate immunity (10). However, Pablo et al. have reported that expression of IL-35 does not differ significantly between patients with plaque-type psoriasis and normal individuals (22) . Thus, the role IL-35 plays in psoriasis and its underlying mechanism are not completely clear. Results of the present study indicate that relative amounts of mRNA of p35 and Ebi3 in PBMCs and the protein concentration of IL-35 in plasma are all lower in patients with psoriasis than in controls. Moreover, the ROC curves we constructed show that these markers can accurately distinguish patients with psoriasis from healthy individuals, especially plasma IL-35 concentration. Th1 cells and related cytokines have been implicated in the pathogenesis of psoriasis (23, 24) . Research has shown that IFN-g is positively correlated with PASI and is capable of activating DC function and inducing IL-23 expression (3, 25) . Expression of TNF-a is reportedly increased in patients with psoriasis and it has functions similar to those of IFN-g, such as activating DC function and upregulating IL-23 expression (1, 25) . Moreover, treatment with TNF-a inhibitor decreases both titers of Th17-related cytokines such as IL-17 and IL-22 and expression of IL-23 (1, 4) . We found that plasma concentrations of IFN-g, TNF-a, IL-23, IL-17 and IL-22 are all high in patients with psoriasis. Furthermore, we found that IFN-g and TNF-a concentrations are negatively associated with those of IL-35, which may be attributable to the fact that IL-35 potentially contributes to the function of T reg and resultant inhibition of proliferation of other T-cell types such as Th1 cells, which facilitate development of autoimmune or inflammatory diseases (2, 7, 8) .
T reg is an important regulatory immune cell in maintenance of peripheral immune tolerance and limiting development of chronic disease or autoimmune disorders (6) . Its initial polarization is stimulated by the synergistic action of cytokines such as TGF-b and IFN-g as well as other T-cell types (1, 2, 6) . Several research groups have reported disequilibrium between T reg and effector T cells in patients; this may provide a basis for the hyperproliferation of pathogenic T cells associated with this disease (2, 6) . T reg dramatically inhibits proliferation of CD4þT cells and production of IFN-g; however, its function with regard to the IL-17 remains complex and unclear (6) . Patients with high PASI scores have significantly increased numbers of peripheral T reg and their numbers are positively associated with the PASI score (5). In another study of the characteristics of Foxp3þT reg and Th17 in pediatric patients with psoriasis, both Th17 and Foxp3þT reg were found to be increased in the peripheral blood and thus considered to have a potential role in pathogenesis (26) . In the present study, TGF-b and IL-10 concentrations were high in patients with psoriasis, possibly as a consequence of the numerous T reg cells in these patients. Furthermore, we found that plasma IL-35 concentrations were positively associated with TGF-b and IL-10, which strongly supports the contention that IL-35 promotes the inhibitory function of T reg , as described earlier.
The role of Th17 cells is currently being emphasized in both antimicrobial and antifungal processes and in autoimmune and inflammatory diseases (5, 26, 27) . Their polarity is partially dependent on the presence of cytokines such as TGF-b and IL-23 (5, 26, 27) . Additionally, Th17 cells are necessary for secretion of IL-17 and IL-22, which directly or indirectly contributes to inflammatory reactions involving keratinocytes (1). IL-17 concentrations are reportedly high in both the blood and skin tissues of patients with psoriasis; thus, disorders of the IL-17 and Th17 pathway may contribute to the chronic inflammation associated with psoriasis (1, 2, (28) (29) (30) (31) . IL-23 is pivotal to the survival and proliferation of Th17 cells and promotes hyperproliferation of keratinocytes, leading to development of psoriasis (1), whereas IL-22 induction of hyperproliferation of keratinocytes is mediated by IL-23, both in vivo and in vitro (32) . There have been reports of strong IL-22 expression in the blood of patients with psoriasis; this could interact with IL-10 receptor B and IL-22 receptor A, which are significantly expressed in epithelial cells such as keratinocytes, to modulate IL-22 function in disease pathogenesis (33, 34) . In the present study, IL-17, IL-22 and plasma IL-23 concentrations were higher in patients with psoriasis than in healthy individuals, which is consistent with findings from previous studies described earlier. Moreover, we identified negative correlations between IL-35 and with the three cytokines that we evaluated. This observation may explain how IL-35 contributes to the inhibitory function of T reg or how it individually limits T-cell proliferation. IL-35 may also inhibit the function of IL-17 or Th17 cells, as described earlier (16) .
In summary, IL-35, an immunosuppressive cytokine, may be involved in the pathogenesis of psoriasis, probably by inhibiting expression of Th1/Th17-related cytokines and inducing expression of T reg -related cytokines, such as TGF-b and IL-10. In the future our research team plans to perform experiments in vitro or in vivo, such as immunohistochemistry studies, to further and more directly characterize expression of IL-35 in skin tissues or other biopsy samples. In this study, we identified statistically significant associations between low IL-35 concentrations and the critical cytokines involved in the pathogenesis of psoriasis. Our primary conclusion is that IL-35 is a potential biomarker for monitoring or diagnosing psoriasis; this possibility needs to be investigated further.
